Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies
Open Access
- 14 December 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 67 (3), 675-680
- https://doi.org/10.1093/jac/dkr491
Abstract
Objectives We designed two different studies to evaluate two different combination antiretroviral therapy (cART) stopping strategies namely a ‘staggered stop’ approach (STOP 1 study) and a ‘protected stop’ approach (STOP 2 study) to find the best ‘universal stop’ strategy. Patients and methods Patients who stopped cART for any reason were recruited. In STOP 1, 10 patients on efavirenz continued dual nucleos(t)ide reverse transcriptase inhibitors (NRTIs) for 1 week after discontinuing efavirenz. Efavirenz concentrations were measured weekly for up to 3 weeks. In STOP 2, 20 patients stopped their cART and replaced it with two tablets of lopinavir/ritonavir (Kaletra) (100/50 mg) twice daily for 4 weeks. Lopinavir, efavirenz, nevirapine and tenofovir concentrations were measured weekly for up to 4 weeks. Virological and resistance testing were performed. Results In STOP 1 five patients still had efavirenz present (median t1/2 = 148.4 h) 3 weeks after stopping. In STOP 2, 15/20 patients had a viral load (VL) of Conclusions Plasma efavirenz concentrations can persist up to 3 weeks after patients stop efavirenz-containing regimens. This suggests a strategy of stopping efavirenz only 1 week before NRTIs may not be long enough for some individuals. The use of lopinavir/ritonavir monotherapy for a 4 week period may be an alternative pharmacologically and virologically effective universal stopping strategy which warrants further investigation.Keywords
This publication has 21 references indexed in Scilit:
- Low Frequency Nonnucleoside Reverse‐Transcriptase Inhibitor–Resistant Variants Contribute to Failure of Efavirenz‐Containing Regimens in Treatment‐Experienced PatientsThe Journal of Infectious Diseases, 2010
- Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimenAIDS, 2008
- Recent developments in the clinical pharmacology of anti-HIV nucleoside analogsCurrent Opinion in HIV and AIDS, 2008
- Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patientsJournal of Antimicrobial Chemotherapy, 2008
- Stopping antiretroviral therapy: role for therapeutic drug monitoringAIDS, 2008
- Partial deletion of CYP2B6 owing to unequal crossover with CYP2B7Pharmacogenetics and Genomics, 2007
- Stopping antiretroviral therapyAIDS, 2007
- Clinical implications of stopping nevirapine-based antiretroviral therapy: relative pharmacokinetics and avoidance of drug resistanceHIV Medicine, 2004
- Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trialAIDS, 2003
- Platelet- and megakaryocyte-derived microparticles transfer CXCR4 receptor to CXCR4-null cells and make them susceptible to infection by X4-HIVAIDS, 2003